Skip Navigation
Visitor Guideline Update: Due to respiratory virus season, children 12 and under are not permitted to visit patients in multiple settings. Additionally, everyone is required to mask in patient rooms and other designated areas. Learn more.

Valve and Structural Heart Disease

Sanger Heart & Vascular Institute is pioneering innovative approaches and devices to redefine structural heart and valve care.

Recent Highlights

Sanger became the first center in the Carolinas to use the new transcatheter Medtronic Evolut™ FX TAVR system to treat patients with aortic stenosis.

Multidisciplinary Valve Care 

For our new Valve Center, we created an innovative, multidisciplinary model that streamlines care and ensures timely access to key tests and images. This shortened the time it takes from patient referral to workup completion by more than three weeks, to an average of 45 days.

Clinical Trials and Innovative Technologies 

  • TRILUMINATE: Sanger was 12th in the world to enroll a patient in this trial of the TriClip™ transcatheter valve repair system in symptomatic patients with severe tricuspid regurgitation. 
  • AltaValve/4C: We performed the 13th case in the U.S. using this transcatheter mitral valve replacement technology.
  • NeoChord: Sanger successfully performed the first-in-human transcatheter mitral valve repair via a trans-septally delivered NeoChord device.  
  • 4D Intracardiac Echocardiography: Sanger was one of the first 20 U.S. sites to utilize this new technology for MitraClip™, TriClip and left atrial appendage cases. 
  • Evolut FX: We were the Carolinas’ first center to use this delivery system for TAVR.
  • Cephea: We were the second U.S. center to use this transcatheter mitral valve replacement technology.
  • EVOQUE: We are the only center in the Carolinas performing transcatheter tricuspid valve replacement with EVOQUE. 
  • ACURATE neo2™: A clinical trial utilizing an innovative valve that may be a good option for certain patients, including those with high pacemaker risk.



Awards and Recognition

  • U.S. News and World Report. Ranked as a high performing hospital in transcatheter aortic valve replacement in 2023 to 2024.

  • Highest rating for TAVR from the society of thoracic surgeons.

    STS/TVT 3-Star Rating

Sanger has performed more than 2,300 TAVR procedures since our program’s inception and we continue to be the most experienced WATCHMAN device implanters in the region.

TAVR

  • TAVR Procedures: Volume from Atrium Health Carolinas Medical Center and Atrium Health Cabarrus (includes aborted procedures). Total being 396. Transfemoral Access being 94 percent. Alternative Access being 6 percent. Source: Internal Data YE 2022; TVT Registry Sept 2021-Aug 2022.

Mitral Valve


  • 59

    Mitral and Tricuspid Valve Procedures
    Internal Data, YTD September 2022 Annualized


  • >90.0%

    Mitral Valve Acute Procedural Success - MR grade ≤ 2+
    TVT Registry, September 2021 - August 2022


  • 0.0%

    30-Day Observed Mortality Rate Unadjusted
    Benchmarks:
    50th Percentile: 0.0%
    90th Percentile: 0.0%
    TVT Registry, September 2021 - August 2022


  • 0.0%

    Mitral Valve In-hospital Mortality Rate Unadjusted
    Benchmarks:
    50th Percentile: 0.0%
    90th Percentile: 0.0%
    TVT Registry, September 2021 - August 2022


  • 0.0%

    Mitral Valve Stroke Rate
    Unadjusted

    Benchmarks:
    50th Percentile: 0.0%
    90th Percentile: 0.0%
    TVT Registry, NCDR

Structural Heart and Valve

  • Line chart depicting increasing referrals and procedures for structural heart and valve, from 410 referrals and 159 procedures in 2015, to 1,523 referrals and 679 procedures in 2022.

Left Atrial Appendage Occlusion


  • >90.0%

    Patients Free of Anticoagulation At 6 Months
    LAAO Registry, January - June 2022

Publications and Presentations

2022 Sanger Heart & Vascular Institute Outcomes and Innovation Report

Close